Size: px
Start display at page:

Download ""

Transcription

1

2

3

4

5

6

7

8

9

10

11

12

13 FANCD

14

15

16 PIG-A PIG-A

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55 é

56 íá ñ

57 ü

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74 de novo

75 JAK2

76

77 AML1-EVI1NUP98-HOXD13 DEK-NUP214 FLT3 FMS RAS AML1 RUNX1 p53 RAS

78 p15 INK4b TET2 RPS14TET2 RPS14

79

80

81 ë

82

83

84

85

86

87

88

89

90

91

92

93

94

95 World Health Organization Classification of Tumors Pathology and genetics Tumor of Haematopoietic and lymphoid tissues WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues WHO histological classification of myelodysplastic syndromes in World Health Organization Classification of Tumours Pathology and Genetics of Tumour of Haematopoietic and Lymphoid Tissues Myelodysplastic syndromes/neoplasms overviewwho Classification of Tumours of Haematopoietic and Lymphoid Tissues http //www jslh com/mds pdf

96

97

98 SHCT monograph vol 18

99 Clinical Practice Guidelines in Oncology Myelodysplastic syndromes V 2

100

101

102

103

104

105

106

107 PIG-A

108 PIG-A

109

110

111

112

113

114 ü PIG-A

115 phosphatidylinositolglycan-classa(pig-a) PIG-A

116 PIG-A Pig-a PIG-A PIG-A

117 PIG-A WT1

118 early growth response factor 1 EGR-1TAX-responsive enhancer element binding protein TAXREB107 human A1 hhr23b Mcl-1 RhoA HMGA2 EGR-1HMGA2RhoA

119

120

121 PIG-A

122

123

124

125 PIG-A PIG-A PIG-A PIG-A PIG-A

126

127

128

129

130

131

132

133 é é

134

135

136

137

138

139

140

141 é é é

142 é ö

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158 Treponema pallidum RHD RHCE

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175 ü ö

176

177

178

179

180 ä

181

182

183

184

185

186

187 JAK2 MPL JAK2 AK2JAK2 MPL TET2 TET2 TET2 C-CBL C-CBL ASXL1 ASXL1 ASXL1 ASXL1 EZH2 EZH2

188 EZH2 BCR-ABL JAK2 MPL JAK2 MPL JAK2 MPL

189

190

191

192

193

194

195 JAK2 JAK2

196 JAK2 JAK2 JAK2 JAK2 JAK2 JAK2 TET2JAK2 JAK2 JAK2JAK2 JAK2 JAK2

197 JAK2

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221 é

222

223

224

225

226

227

228

229

230

231

232

233

234

235 DKC

236 DKC TERC TERT NOP NHP TINF

237

238

239

240

241

242

243

244

245 RPS RPS RPL RPLRPL a

246

247

248 RPS

249

250

251

252

253 é

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269 ALAS2 ALAS2 ALAS2

270 ALAS2 ALAS2 SLC25 A38 PUS1 SLC25 A38 PUS1 ABCB7 GLRX5 SLC19A2 SLC19A2 SLC19A2

271 GLRX5 GLRX5 ABCB7PUS1

272 Glutaredoxin5 ABCB7 SLC25A38SLC25A38 ALAS2 SCL19A2 Pseudouridyate synthase 1 gene PUS1

273

274 PUS1

275

医師国家資格試験出題基準(平成17年版)

医師国家資格試験出題基準(平成17年版) ü é é ö ! éè é ö ö é ö ö ö ö ! é ! ! !! !! !! ! ! ! ! ! ! ! !! !! !! " !! !!!!!!! !!!!! ! "! !!!!!

More information

’¸’_Ł\”ƒ1-4fiñŒÊ

’¸’_Ł\”ƒ1-4fiñŒÊ 20 23 2011 1 23 24 10 2010 26 11 20 27 12 29 13 22 35 14 2010 36 15 44 23 3 11 23 27 1 11 46 14 188 14 2 16 22 97 3 2 7 3 30 80 19 22 10 1 37 796 4 3 20 30 30 23 3 30 19 4 1 4 8 1 2 4 5 2010 73 22 7 19

More information

扉*-p02_OCF4.1

扉*-p02_OCF4.1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 ü 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70

More information

untitled

untitled 700 1 2 2 3 4 5 PDF 6 7 8 9 300 400m 1:2.5 1:1.8 75 3.2 10 11 12 1) 1998 Vol1 2) 1987-1992 3) 2001-2002 1-24 4) 1996 17 6-7 5) 2000 31 587-590 6) 2002 22 13 7) 2005 2005 20 46 1 2 3 4 5 6 7 8 9 10 11

More information

ISBN4-902715-40-6 i ii iii iv 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 Régime de la Terreur 35 é è 36 37 38 39 40 41 42 43 44 45 46 ü 47 48 49 50

More information

Japan Atherosclerosis Society (JAS) Guidelines for Diagnosis and Treatment of Atherosclerotic Cardiovascular Diseases Contents Chapter 1 Chapter 5 Chapter 2 Chapter 6 Chapter 3 Chapter 7 Chapter 4 Chapter

More information

14 13 12 11 10 9 8 7 6 5 4 3 2 1 B1 B2 N

14 13 12 11 10 9 8 7 6 5 4 3 2 1 B1 B2 N 14 13 12 11 10 9 8 7 6 5 4 3 2 1 B1 B2 N L B1 K M K 1F 2F 2 j 5 L 3F 4F É 5F 6F 7F 8F & 9F 10F k & 11F 14F 12F 14F 10 13F 12F 1 2 3 11 12 13 15 14 16 4 5 28 17 7 12 6 19 18 27 8 11 10 9 1 2 3 4 5 6 7 8

More information

B 温泉用語集v2 ABC順090617.xls

B 温泉用語集v2 ABC順090617.xls é é é üü é ßä ö ß ä é é é ß ö é é ü üö ä é é é é é ä é ä ä éé ä ä ä ä é é éé é Ü é ü é à ä ä ü ö ß ä é â é éé é ß ä ä éé é ö é é ä é é é éé éè éé ä é ü ßß ö œ ß üß à éé é éé é éé é ü ö é ää ä ßßä éé ä

More information

13 1 17 1942 1980 7 1 1 2

13 1 17 1942 1980 7 1 1 2 É 22(1889) 2 5(1916) 3 478 478 518 478 4 CD-ROM 1 75 171 301 347 CD-ROM É 1 13 1 17 1942 1980 7 1 1 2 CD-ROM 1990 22 2 23 5 16 3 22 4 1 110 29 3 193 193 32 7 195 32 8 193 195 32 5 19 11 32 13 21 44 10

More information

untitled

untitled š š ( œ ) 1,000 23. 3.16 105,041,779 81,238,942 23,802,837 60,287,753 23,802,084 7,692,084 6,310,000 9,800,000 753 753 4,195,443 2,864,813 166,352 1,164,278 56,092,310 1,182,200 105,650 105,650 4,460 50,000,000

More information

Ÿ š ( š ) 300,000,000 14. 3.22 116,500,963 40,185,547 76,315,416 81,749,456 76,275,801 965,801 63,510,000 11,800,000 39,615 39,615 3,227,059 3,227,059

Ÿ š ( š ) 300,000,000 14. 3.22 116,500,963 40,185,547 76,315,416 81,749,456 76,275,801 965,801 63,510,000 11,800,000 39,615 39,615 3,227,059 3,227,059 š ( š ) Ÿœ f 240,000 240,000 130,000 240,000 100,000 240,000 110,000 500,000 240,000 3 240,000 500,000 240,000 240,000 500,000 240,000 500,000 100,000 200,000 200,000 90,000 4,106,000 500,000 14. 4. 1

More information

untitled

untitled š ( ) œ I 100,000 100,000 100,000 100,000 100,000 100,000 I f 100,000 100,000 100,000 100,000 100,000 100,000 2,000,000 110,000 I 70,000 800,210 4,642,500 (1) 2,366,860 22.11.16 24. 3.15 0 0 24. 5.28 23,351,338

More information

第79回_プログラム.indd

第79回_プログラム.indd Regulation of ghrelin signaling by a leptin-induced gene, negative regulatory element-binding protein, in the hypothalamic neurons. Phase I clinical trial using peptide vaccine for human vascular endothelial

More information

1945 47 10 11 12 13 14 792 2003272 273 53 35 54 54915 1999 101994 1999 125715 1999 11451 200322 123 12 45 2 2003 10 11 21 23 13 2 2003 14 15 2003 22 2

1945 47 10 11 12 13 14 792 2003272 273 53 35 54 54915 1999 101994 1999 125715 1999 11451 200322 123 12 45 2 2003 10 11 21 23 13 2 2003 14 15 2003 22 2 2003 20 23 2003 2003 10 2003 14 2003 12 2003 82 3 2003 23 24 198879 2003 9 2003 2004 1152 103 1945 47 10 11 12 13 14 792 2003272 273 53 35 54 54915 1999 101994 1999 125715 1999 11451 200322 123 12 45 2

More information

TABLE of CONTENTS 11 51 65 187 1 2 3 4 5 6 é é 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59

More information

1

1 1 1. 2 1-1. 2 3 1-2.2 4 2. 5 6 7 2-1 2-2 2-3 2-4 2-5 2-1 2-2 2-3 2-4 2-5 PDF PDF 8 P10 9 2-1. 10 2-1. 11 2-1. ( ( 12 2-1. 24 13 2-1. 3 3 14 2-1. 15 2-2. 16 17 2-2. 3 18 2-2. 19 2712 3 1000 20 2841 21 ...

More information

Microsoft Word - 修正版2 第一部提出.doc

Microsoft Word - 修正版2 第一部提出.doc 1 myelodysplastic syndromes, MDS MDS MDS MDS anemia of chronic disordersacd aplastic anemia, AA 8 MDS 2005 Mufti idiopathic cytopenias of uncertain significance, ICUS MDS 2006 MDS A ACD MDS MDS B MDS International

More information

CharacterSets.book Japanese

CharacterSets.book Japanese FRAMEMAKER 9 ADOBE i................................................. 2 1 2 1 2 3 4 ú þ ý! " # $ % & ( ) * +, -. / 0 1 2 3 4 5 5 6 7 8 9 : ; < = >? @ A B C D E F G H I J K L M N O P Q R S T U 6 V W X

More information

š ( š ) Ÿ 1,681,268 100,000 16,519,700 (826) 1,661,677 17. 3.31 55,613,224 865,273 54,747,951 55,613,224 2,568,266 2,568,266 52,179,685 52,179,685 33,

š ( š ) Ÿ 1,681,268 100,000 16,519,700 (826) 1,661,677 17. 3.31 55,613,224 865,273 54,747,951 55,613,224 2,568,266 2,568,266 52,179,685 52,179,685 33, Ÿ š ( š ) 400,000 60,000 60,000 1,000,000 100,000 120,000 60,000 120,000 60,000 120,000 120,000 120,000 120,000 120,000 120,000 1,200,000 240,000 60,000 60,000 120,000 60,000 120,000 60,000 600,000 120,000

More information

O157 6/23 7/4 6 25 1000 117,050 6 14:00~15:30 1 2 22 22 14:30~15:30 8 12 1 5 20 6 20 10 11 30 9 10 6 1 30 6 6 0 30 6 19 0 3 27 6 20 0 50 1 2 6 4 61 1 6 5 1 2 1 2 6 19 6 4 15 6 1 6 30 6 24 30 59

More information

みさき_1

みさき_1 2 3 4 5 6 7 1F 2F 8 9 10 11 17 18 19 20 21 22 23 24 31 25 26 27 28 29 30 8 1 2 3 4 5 6 7 6 8 7 16 7 8 9 10 11 12 14 15 13 17 23 Vol.41 8 6 20 11 7 15 7 23 7 7 7 16 23 23 8 13 18:00 22:00 722

More information

Vol..3 2010 2 10 2

Vol..3 2010 2 10 2 1 Vol..3 2010 2 10 2 Vol..3 2010 2 10 3 Vol..3 2010 2 10 4 Vol..3 2010 2 10 5 Vol..3 2010 2 10 6 Vol..3 2010 2 10 7 Vol..3 2010 2 10 8 Vol..3 2010 2 10 9 Vol..3 2010 2 10 10 Vol..3 2010 2 10 11 Vol..3

More information

H21_report

H21_report vol.4 1 2 6 10 14 18 20 22 24 25 1 2 2172 73 3 21925 926 21125 126 4 5 6 21629 630 7 21107 108 21127 128 8 9 10 21616 617 11 211026 1027 211213 1214 12 13 14 21713 714 15 2194 95 211031 111 16 17 18 19

More information

2009-9-2.indd

2009-9-2.indd Q No.1441 Q No.1442 Vol.33 NO.9 (2009) 30 (614) Q No.1443 Vol.33 NO.9 (2009) 31 (615) Q No.1444 Vol.33 NO.9 (2009) 32 (616) Vol.33 NO.9 (2009) 33 (617) Vol.33 NO.9 (2009) 34 (618) Q No.1445 Vol.33 NO.9

More information

untitled

untitled Vol.27 1 Vol.27 2 Vol.27 3 Vol.27 4 Vol.27 5 Vol.27 6 Vol.27 7 Vol.27 8 Vol.27 9 Vol.27 10 11 Vol.27 Vol.27 12 Vol.27 13 Vol.27 14 Vol.27 15 Vol.27 16 Vol.27 17 Vol.27 2007 10 29 18 http://www.nira.or.jp/index.html

More information